Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is expected to generate significant revenue from their product candidate pipeline, with peak annual sales projected to approach $640 million by the mid-2030s. This optimistic outlook is supported by an increase in projected pricing per patient and a maximum projected market penetration of just over 2,100 patients. Furthermore, the potential approval and commercialization of SGT-610 in high-frequency BCC could more than double the company's total addressable market, further boosting revenue potential and driving an increase in the company's 12-month price target to $110 per share.

Sol-Gel Technologies is facing significant risks in achieving its price target, including the possibility of setbacks with its other drug programs and the potential for medium- to long-term dilution risk. The company's valuation of $424M is based on a discounted cashflow analysis, with a forecasted value of $400M for its key drug candidate, SGT-610. However, the success of this drug in the pivotal Phase 3 trial in Gorlin syndrome patients is crucial, with potential FDA approval not expected until late 2027 and possible launch in 2028. With these uncertainties and potential delays, there is currently a negative outlook on the company's stock.